How do I prescribe and manage mIDH inhibitors in patients with IDH-mutant glioma?

IF 2.4 Q2 CLINICAL NEUROLOGY Neuro-oncology practice Pub Date : 2024-12-03 eCollection Date: 2025-02-01 DOI:10.1093/nop/npae112

Megan E H Still, Rachel S F Moor, Ashley P Ghiaseddin, Annette Leibetseder, Andreas F Hottinger, Anna Berghoff, Denise Leung

引用次数: 0

Abstract

Recent interest has been in using mIDH inhibitors in patients with IDH-mutant gliomas. This review paper summarizes the indications, side effects, recommended dosing, and management for patients on ivosidenib and vorasidenib.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

如何在idh突变型胶质瘤患者中开具和管理mIDH抑制剂？

最近的兴趣是在idh突变胶质瘤患者中使用mIDH抑制剂。本文综述了伊沃西迪尼和沃拉西尼的适应症、副作用、推荐剂量和治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Neuro-oncology practice CLINICAL NEUROLOGY-

CiteScore

5.30

自引率

11.10%

发文量

期刊介绍： Neuro-Oncology Practice focuses on the clinical aspects of the subspecialty for practicing clinicians and healthcare specialists from a variety of disciplines including physicians, nurses, physical/occupational therapists, neuropsychologists, and palliative care specialists, who have focused their careers on clinical patient care and who want to apply the latest treatment advances to their practice. These include: Applying new trial results to improve standards of patient care Translating scientific advances such as tumor molecular profiling and advanced imaging into clinical treatment decision making and personalized brain tumor therapies Raising awareness of basic, translational and clinical research in areas of symptom management, survivorship, neurocognitive function, end of life issues and caregiving

期刊最新文献

Foreword. Role of the tumor board when prescribing mutant isocitrate dehydrogenase inhibitors to patients with isocitrate dehydrogenase-mutant glioma. Financial challenges of being on long-term, high-cost medications. How do I prescribe and manage mIDH inhibitors in patients with IDH-mutant glioma? Vorasidenib: Patient and caregiver information sheet.